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Introduction
All the types of diabetes mellitus(DM) in pregnancy – 
pre-gestational diabetes mellitus (PGDM) and gestational 
diabetes mellitus(GDM) are associated with a significantly 
increased risk of short and long-term maternal, fetal and 
neonatal adverse outcomes[1, 2, 3]. The risk of developing 
pregnancy complications is associated with increased ma-
ternal blood glucose levels and it is 2 to 5 times higher in 
women with type 1 diabetes mellitus (T1DM) compared to 
the general population. Furthermore, there is evidence that 
type 2 diabetes mellitus (T2DM) in pregnancy has a similar 
impact on infants as T1DM [4, 5], and PGDM has a greater 
negative impact on pregnancy outcomes compared to preg-
nancies complicated with GDM [2].
Despite the significant progress achieved in glycemic 
control in pregnant women with DM, pregnancy complica-
tions are still very common, especially in case of PGDM [6].
Short-term adverse outcomes can be divided into com-
plications that occur: in utero (diabetic fetopathy, fetal mac-
rosomia, intrauterine growth restriction, congenital mal-
formations, antenatal fetal death); during labor (shoulder 
dystocia, birth injuries, intranatal death) and during the 
neonatal period (respiratory distress syndrome, metabolic, 
electrolytic and hematological disorders, hypertrophic car-
diomyopathy, neonatal mortality).  Long-term fetal out-
comes include: overweight and obesity, impaired glucose 
tolerance or T2DM, metabolic syndrome with increased 
risk of cardiovascular disease and subtle neurophysiological 
dysfunctions.
Adverse fetal outcomes of a diabetic pregnancy can also 
be classified according to trimesters:
DOI: 10.5281/zenodo.1106903
UDC: 618.3-06:616.379-008.64
Fetal and neonatal complications of diabetic pregnancy
Rosca Daniela, MD, Post-graduate Student
Scientific Laboratory of Obstetrics, Institute of Mother and Child, Chisinau, the Republic of Moldova
Corresponding author: dana_roshca@yahoo.com.  Received October 24, 2017; accepted December 08, 2017  
Abstract
Background: There is currently convincing clinical and experimental evidence that a hyperglycemic intrauterine environment is responsible not only 
for significant short-term outcomes in the fetus and newborn infant, but it is also an increased risk for long-term outcomes, such as developing diabetes 
mellitus and other chronic diseases in adulthood. Short-term complications can occur in utero (i. e. diabetic fetopathy, fetal macrosomia, intrauterine 
growth restriction, congenital malformations, intrauterine fetal death); during labor (shoulder dystocia, birth injuries, intranatal death) and during the 
neonatal period (respiratory distress syndrome, metabolic, electrolytic and hematological disorders, hypertrophic cardiomyopathy, neonatal mortality). 
The risk of adverse outcomes is greater in pre-gestational diabetes, but undiagnosed and / or poorly controlled gestational diabetes can lead to similar 
consequences. Although there is currently a relatively clear view on the pathogenesis of fetal and neonatal complications of maternal diabetes and their 
interconnections, the deep molecular mechanisms are far from being clearly understood. Furthermore, there has been an unexpected increase in the 
incidence of gestational diabetes worldwide during the last decades,  in association with the obesity pandemic and type 2 diabetes.
Conclusions: Maternal diabetes, especially pre-gestational diabetes has a significant impact on the incidence of fetal and neonatal complications with 
both short and long-term outcomes.
Key words: pregnancy, diabetes mellitus, gestational diabetes, diabetic fetopathy.
·	First trimester – congenital malformations, fetal loss, 
intrauterine growth restriction;
·	Second trimester – hypertrophic cardiomyopathy, er-
ythremia, fetal loss, low intelligence coefficient;
·	Third trimester – hypoglycemia, hypocalcaemia, hy-
perbilirubinemia, respiratory distress syndrome, mac-
rosomia, hypomagnesaemia, intrauterine fetal death 
[48].
Adverse fetal outcomes of diabetic pregnancy
Diabetic Fetopathy (DF) is a complex and heteroge-
neous syndrome that develops in the fetus during the intra-
uterine period and is induced by genetic or acquired disor-
ders of insulin secretion and / or peripheral cell resistance 
to insulin action and is characterized by specific phenotypic 
changes, congenital defects, significant metabolic and func-
tional disorders of the newborn [7].
The definition of “diabetic fetopathy” is mainly used in 
Russian specialty literature and it is uncommon in Anglo-
American literature, being partly replaced by the term of 
“diabetic macrosomia”, with emphasis on birth complica-
tions such as shoulder dystocia, hypoxia and others, without 
counting the metabolic changes in this context [8].
The carbohydrate metabolism disorders during preg-
nancy contribute to the development of DF, which is most 
frequently characterized by macrosomia or intrauterine 
growth restriction (IUGR) and is one of the most serious 
and specific manifestations of maternal DM in the new-
born, which increases the risk of birth trauma, perinatal 
morbidity and mortality [9].
The literature data on the frequency of DF is contradic-
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tory. The incidence of DF ranges between 5.7% and 75.5% 
and depends on the type and degree of compensation of 
the maternal DM, the presence of vascular complications, 
associated obstetrical and extra-genital disorders, and the 
population that is subject to research. According to some 
authors, most newborns from mothers with T1DM (96%) 
and T2DM (85%) show signs of DF and only 49% of infants 
from mothers with GDM will develop these signs.[11].
Macrosomia. The concept of excessive fetal growth is 
expressed either by “macrosomia” or “large for gestational 
age” [12, 14, 15].
There is no general consensus on the definition of mac-
rosomia or the underlying principles of diagnosis. Most re-
cent studies and meta-analyses define macrosomia as birth 
weight ≥4,000 g. The American College of Obstetricians 
and Gynecologists recommends as a reference the weight 
of ≥4,500 g due to substantial increase of the rate of ma-
ternal, fetal and neonatal complications. Nevertheless, there 
is considerable variation in the definition of macrosomia 
(≥4,000 g, ≥4,100 g, ≥4,200 g, ≥4,500 g, ≥4,536 g regard-
less of gestational age, > 90th percentile, > 95th percentile or 
2 deviations standard above the mean weight for corrected 
gestational age, gender and ethnicity) [12, 14, 15, 17, 23, 24].
Defining macrosomia with an absolute fixed birth weight 
has the advantage of making it easier to determine and re-
member, but does not take into account the influences of 
gestational age on the birth weight. Defining it as a new-
born large for gestational age offers a potential solution for 
this problem. However, infants that are large for gestational 
age are also defined differently: infants with a body weight 
above the 90th percentile or the 95th percentile or greater 
than 2 standard deviations for the gestational age corrected 
for sex and ethnicity [6, 12, 18, 25].
Fetal macrosomia is the most common consequence of 
diabetic pregnancy, that usually becomes obvious from the 
26-28th gestational week [26, 27] and its severity is mainly 
influenced by the maternal blood glucose level [14, 27]. Li-
terature data on macrosomia frequency differs significantly 
by country and type of DM [16]. The prevalence of macro-
somia in developed countries varies from 5% to 20% [15], 
and in developing countries - from 0.5% to 14.9% [14].
The prevalence of macrosomia studied in many coun-
tries of the world significantly varies from 1% (Taiwan) to 
28% (Denmark), with the highest rates (20%) in Northern 
countries [16].
According to a recent study, the overall rate of macro-
somia for the non-diabetic population is 7-9%, increasing 
to 20-45% in GDM [3]. Fetal macrosomia (birth weight 
≥4,000 g) is found in 15-45% of newborns from mothers 
with GDM, 47% of mothers with T1DM compared to 12% 
of neonates from pregnant women without DM. In the last 
2-3 decades, the incidence of macrosomia increased by 15-
25% and is worldwide associated with increased rates of 
obesity and maternal DM [15, 19, 29, 30].
Fetal macrosomia can be estimated using clinical data 
(assessment of uterine height and maternal medical his-
tory), determination of insulin levels in the amniotic fluid, 
requiring an invasive procedure – amniocentesis, and ul-
trasound scans. Fetal ultrasound scan became an indispen- 
sable part of an obstetrical examination and is the elective 
method for the antenatal estimation of fetal weight [12]. 
Some studies demonstrated that the Ott, Hadlock IV and 
Coombs formulas are preferred for estimating fetal weight 
in fetuses <2,500 g and> 4,000 g. Formulas that combine all 
three parameters (bi-parietal diameter, femur length and 
abdomen circumference) provide the best estimation of fe-
tal weight in terms of general accuracy and do not indicate a 
tendency to overestimate or underestimate real weight [12, 
17, 23, 31].
There is evidence that serial biometric ultrasound scan 
throughout pregnancy, especially the evaluation of fetal ab-
domen circumference in the third trimester, can improve the 
predictive accuracy of fetal macrosomia in pregnant women 
with DM [24, 32, 33].  The majority of macrosomia predic-
tion studies are based on ultrasound measurements of one 
parameter (abdominal circumference or subcutaneous tis-
sue thickness) or combinations of measurements (abdomi-
nal circumference, biparietal diameter, femur length, and 
head circumference) to estimate fetal weight [12, 17, 23, 31]. 
Although the combined fetal biometric parameters or serial 
evaluation throughout pregnancy provide the best estima-
tion of fetal weight, a recent meta-analysis revealed the uti-
lity, safety, and sufficiency of  fetal abdominal circumference 
measurement only after 24 weeks of gestation for the estima-
tion of  newborns as large or small for gestational age [12]. 
Despite the fact that DM modifies the parameters of fe-
tal biometry with the increase of the thoracic-abdominal 
parameter, there is still a lack of precision of the antenatal 
diagnosis of macrosomia using the ultrasound scan – insuf-
ficient method with a positive predictive value of only 65% 
for the detection of a fetus ≥4,000 g [16].
The effectiveness of three-dimensional ultrasound in the 
estimation of fetal weight is contradictory. Some authors 
have demonstrated that this method improves the estima-
tion of fetal weight [12, 23, 24] and other studies have found 
the superiority of two-dimensional ultrasound performed 
2 weeks before birth in predicting the birth weight of the 
newborn and fetal macrosomia in pregnant women with 
DM [24, 34].
Therefore, scientific literature confirms that the predic-
tion of fetal macrosomia is complicated. Ultrasound scan 
was recognized as the most accurate method of estimating 
fetal weight. Unfortunately, the average error varies within a 
300-550 g range, and ultrasound assessment of fetal weight 
adds some useful additional information to clinicians in es-
timating macrosomia [33].
Multiple conclusive clinical and experimental studies 
showed the association of PGDM (T1DM and T2DM) or 
GDM with macrosomia. DM remains a major cause of mac-
rosomia despite improved obstetrical care [1, 12, 18].  Gly-
cemic parameters of diabetic pregnant women in the third 
trimester are stronger predictors of fetal growth than blood 
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glucose levels in the I and II trimesters or in preconception 
period, the latter being more commonly associated with 
lower birth weight [35,36,37 ].
The first meta-analysis of epidemiological studies pub-
lished in 2015, which explored the significance of GDM as 
an independent risk factor for macrosomia, included 5 co-
hort studies and 7 case-control studies. The authors found 
that GDM was associated with macrosomia independently 
from other risk factors (pre-gestational body mass index, 
pre-pregnancy obesity, pathological weight gain in preg-
nancy) [39]. Each type of DM is an independent risk factor 
for macrosomia [1, 12, 18], and effective treatment of hyper-
glycemia in pregnancy significantly reduces the rate of fetal 
macrosomia [14, 38].
According to Pedersen’s hypothesis, the macrosomia ob-
served in pregnant women with DM is a consequence of fetal 
hyperinsulinemia, a secondary condition of maternal hyper-
glycemia. Fetal hyperinsulinemia causes an increased use of 
cellular glucose, which contributes to hepatic glycogen de-
posit formation, decreases lipid mobilization and increases 
protein production. Insulin stimulates the incorporation of 
amino acids into proteins and in diabetic pregnancy it in-
creases the assimilation of amino acids and protein synthesis 
and decreases protein catabolism. During the last 12 weeks 
of gestation, the fetus of a diabetic mother stores 50-60% 
more fat than the fetus of a mother without DM [19].
Fetal growth is the result of maternal hyperglycemia 
with increased trans-placental transfer of maternal glucose 
leading to fetal hyperglycemia (glucose being an important 
anabolic nutrient), the stimulation of insulin release by fetal 
β-pancreatic cells (hyperinsulinemia, insulin being an im-
portant anabolic hormone) and, as insulin is a major factor 
in fetal growth, it leads to macrosomia and other complica-
tions with an increased risk of developing obesity, T2DM 
and cardiovascular disease in adolescence or youth years. 
Pederson’s hypothesis is fundamental for understanding the 
physiopathological consequences of DM during pregnancy. 
Subsequently, this theory has been modified to include the 
contributions of other nutrients in increased concentrations 
(amino acids, lipids, insulin growth factor) that may con-
tribute to fetal hyperinsulinemia [3, 15, 19, 28, 51, 52].
Fetal hyperinsulinemia has the following effects:
·	Excessive growth of insulin-sensitive tissues such as 
adipose tissue (especially around the chest, shoulders 
and abdomen), organomegalia (especially of the liver, 
spleen and heart) and accelerated maturation of the 
skeleton, which increases the risk of shoulder dystocia, 
perinatal mortality, birth trauma and the rate of cesa-
rean section surgeries;
·	Neonatal metabolic, electrolytic and hematological 
complications: hypoglycemia, hypocalcemia, hyper-
phosphatemia, hypomagnesemia, polycythemia, hy-
perbilirubinemia;
·	 In utero hypoxemia develops, which may increase the 
risk of antenatal mortality, polycythemia, hyperbiliru-
binemia and venous renal thrombosis of the fetus;
·	 Increased risk of long-term outcomes such as obesity 
and DM in childhood [6, 12]. 
Experimental and clinical studies found that fetal hy-
perinsulinemia is strongly associated with fetal macrosomia 
and increased adipose tissue. However, the high frequency 
of fetal macrosomia in diabetic pregnant women with ade-
quate glycemia control and in pregnant women without DM 
confirms the involvement of factors other than maternal 
hyperglycemia and fetal hyperinsulinemia, in the develop-
ment of fetal macrosomia [19].
While maternal hyperglycemia and fetal hyperinsu-
linemia are considered the main causes for excessive fetal 
growth, the exact aspects of the underlying mechanisms 
of macrosomia remain less clear. Not only poor glycemic 
control before and throughout pregnancy is a cause of fe-
tal macrosomia but also hormonal, genetic, environmental, 
and constitutional factors, an angiopathy of utero-placental 
vessels with fetal subsequent hypoxia contributes to the 
development of fetal macrosomia. DM and poor glycemic 
control, pre-gestational obesity, pathological weight gain in 
pregnancy, a history of macrosomia, and parity are the main 
risk factors for macrosomia. Despite all these risk factors, 
many aspects of the weight at birth remain inexplicable [12, 
40, 41, 42, 43].
For practical reasons, the causes of fetal macrosomia 
can be divided into non-modifiable factors (genetic factors, 
male gender, parity, age and maternal height) and modi-
fiable maternal factors (pre-pregnancy body mass index, 
pathological weight gain, nutritional intake, the level of 
physical activity, smoking and metabolic parameters, espe-
cially DM and dyslipidemia) [32].
Although DM and maternal obesity are independently 
associated with pregnancy complications, the combination 
of T2DM or GDM with pre-gestational obesity has a greater 
effect on macrosomia and is associated with higher perina-
tal morbidity rates [6, 19].
Macrosomia, regardless of the cause, is associated with 
a higher risk for maternal complications (prolonged labor, 
birth assisted with forceps or vacuum, caesarean delivery, 
maternal trauma, postpartum hemorrhage) and neonatal 
complications: premature birth and complications associa-
ted with prematurity (respiratory distress syndrome, infec-
tion, jaundice, transfer to neonatal intensive care unit and 
perinatal mortality), birth injuries (shoulder dystocia, bra-
chial plexus palsy, clavicle and humerus fractures), neonatal 
hypoglycemia, perinatal asphyxia, meconium aspiration, 
congenital abnormalities [12, 14, 18, 19, 20].
Therefore, fetal macrosomia is an obstetrical condition 
that affects an average of 10% of all pregnancies and may be 
associated with severe maternal, fetal and neonatal adverse 
outcomes. An early identification of risk factors (pre-gesta-
tional obesity, pathological weight gain, PGDM and GDM) 
allows applying the measures needed to prevent perinatal 
complications.
Intrauterine growth restriction (IUGR)
Infants with a birth weight below the 10th percentile are 
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considered small for gestational age. IUGR is more rarely 
associated with DM, and it occurs in about 20% of diabe-
tic pregnancies, more frequently in pregnant women with 
T1DM with severe renal-vascular complications compared 
to a 10% incidence in infants born to mothers without DM. 
Maternal renal-vascular disorder is a common cause of the 
impairment of fetal growth in pregnancies complicated with 
DM. The newborns considered small for gestational age 
have an increased risk of low Apgar score at birth, respira-
tory distress syndrome, neonatal death, cardiovascular and 
metabolic disorders during the life [20].
Congenital malformations of neonates from diabetic 
pregnant women are the main cause of perinatal and infan-
tile death. The risk of major congenital malformations in 
pregnancies complicated with DM is 2-5 times higher than 
in the general population, congenital abnormalities occur in 
4-12% of cases [16,20], and in pregnant women with decom-
pensated forms of DM the risk increases up to 20% [14, 20].
The most common congenital anomalies are the follo-
wing [15, 26, 45, 46]:
·	Cardiac: transposition of the great vessels, atrial septal 
defect or ventricular septum defect, aortic co-arcta-
tion, persistent truncus arteriosus, single ventricle;
·	Of the central nervous system: anencephaly, micro-
cephaly, encephalocele, meningomyelocele, holo-
prozencephaly, spina bifida;
·	Skeletal: caudal regression syndrome (agenesia or hy-
poplasia of the sacral and coccidian bone, sometimes 
of lumbar vertebrae), femoral dysplasia;
·	Renal: renal agenesis, hydronephrosis, duplicated ure-
ter;
·	Gastro-intestinal: duodenal atresia, anorectal atresia;
·	Others: palatoschisis, microftalmia, intestinal atresia.
Newborns of mothers with PGDM are more likely to de-
velop congenital malformations, with a similar incidence in 
both types of PGDM, and the development risk is highly 
associated with the length of DM before pregnancy [15, 20, 
44, 45, 46].
Several authors reported an association between GDM 
and the same types of congenital malformations diagnosed 
in the descendants of women with PGDM, although some 
studies found a limited association of GDM with some 
congenital defects. The risk of congenital abnormalities in 
neonates of mothers with GDM is lower than the risk for 
neonates of mothers with PGDM [15, 44, 47]. The risk of 
congenital malformations does not significantly vary in 
women with T1DM and T2DM, being 1.9-10 times higher 
in the PGDM, 1.7-3 times higher in T1DM compared to the 
general population. In the case of GDM, the risk of congeni-
tal malformations is moderate and is slightly increased (1.1-
1.3 times higher) compared to the general population, but 
is much lower than in women with PGDM and is probably 
also determined by cases of undiagnosed T2DM in patients 
with GDM [15, 44].In newborns of mothers with PGDM, 
the incidence of heart defects varies from 2 to 34 cases per 
1,000 births, central nervous system abnormalities – from 1 
to 5 cases per 1,000 births, musculoskeletal malformations 
– from 2 up to 20 cases per 1000 births, genital-urinary ab-
normalities – from 2 to 32 cases per 1,000 births and gastro-
intestinal defects – from 1 to 5 cases per 1,000 births [44, 49].
It is difficult to compare the frequency of congenital ab-
normalities associated with maternal DM due to the differ-
ences in diagnostic criteria of DM in different countries. It is 
also difficult to compare maternal DM rates among popula-
tions where the screening of the disease is not similar in all 
centers. 
The results of several studies on the risk of congenital ano- 
malies in neonates of mothers with GDM showed the 1.2-
fold increase in congenital malformations for GDM com- 
pared to the general population. Pregnant women with GDM 
with a basal hyperglycemia > 120 mg / dl (> 6.7 mmol / l) 
or HbA1c ≥ 7.0% have a 3.4-fold higher risk, and for women 
with GDM with normal basal glucose there is no difference 
of risk compared to women without DM. It was found that 
there is a small, but statistically significant increase in the 
frequency of holoprosencephaly, bone abnormalities and 
genitourinary system malformations in children of mothers 
with GDM compared to non-diabetic pregnant women [44].
The pathogenesis of fetal malformations associated with 
PGDM is partially understood, but it is multi-factorial and 
correlates with several deficiencies of toxic nutrients or me-
tabolites. Hyperglycemia, hypoxia, ketonemia, amino acid 
abnormalities and protein glycosylation were reported as 
potential teratogenic factors that may affect molecular sig-
naling pathways with adverse effects on embryogenesis [15, 
18, 20].
Embryo-developmental disorders during pregnancy 
complicated with DM were extensively explored in experi-
mental and clinical studies. Available data indicate that there 
are many changes in the embryonic environment capable 
of inducing teratogenic development. The most important 
change is the increase in glucose concentration, which has 
a number of direct metabolic consequences on the embryo. 
However, there are other modifications with teratogenic ef-
fects - the excess of reactive oxygen molecules, elevated le-
vels of ketone bodies and branched chain amino acids in the 
tissues of different fetal organs, but their mechanism of ac-
tion still has to be elucidated. Likewise, newborn rats from 
mothers with chemically induced DM have an increased 
oxidative stress in different tissues, and there is an increase 
in reactive oxygen molecules and lipid peroxidation in the 
liver, kidney, brain and skin, and elevated levels of lipid pe-
roxides in plasma [8, 14, 20].
Therefore, maternal DM, especially PGDM, has colossal 
consequences on the incidence of congenital anomalies [14, 
16, 20].
Intrauterine fetal death. Approximately 50% of the 
cases of dead fetus births are related to uncontrolled mater-
nal hyperglycemia, and the other cases are caused by fetal 
congenital infections or anomalies, placental insufficiency, 
maternal diseases. This increased risk is most commonly as-
sociated with T1DM, but it can also be encountered in other 
forms of DM. Compared with the general population, the 
risk of fetal mortality is 3-5 times higher in pregnant women 
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with T1DM, 2-3 times higher in women with T2DM, and 
pregnant women with GDM have a lower risk than women 
with PGDM. The birth of a dead fetus in pregnant women 
with DZG is more common at gestational age, suggesting 
that maternal hyperglycemia causes hyperinsulinemia and 
fetal lactic acidosis – the main causes of intrauterine death 
[13]. Antenatal fetal death in pregnant women with GDM is 
more common for gestational age fetus, suggesting that ma-
ternal hyperglycemia causes hyperinsulinemia and fetal lac-
tic acidosis – the causes of intrauterine death [13]. Hypoxia 
and fetal heart failure, secondary to poor glycemic control, 
are probably the most important factors for antenatal mor-
tality among pregnant women with DM [13].
Complications related to labor and delivery
Shoulder dystocia is a rare but serious obstetric com-
plication that occurs in neonates with macrosomia and 
may lead to paralysis of the brachial plexus, fracture of the 
clavicle or of the humerus [15, 20]. In Denmark, the risk 
of shoulder dystocia among vaginal births is 6% at women 
with T1DM. A quarter of these neonates need resuscita-
tion at birth, and some suffer from lesions of the bones and 
nerves. The incidence of brachial plexus paralysis and frac-
tures of neonates born alive from mothers with PGDM is 10 
times higher than in the general population [8, 20].
Preterm birth, being one of the major causes of fetal 
death, is found in about 10% of the pregnancies, in 50% of 
women with DM and is 4.8 times higher in pregnant women 
with DM than in the general population [21]. Patients with 
T1DM have an increased risk of premature birth. Recent co-
hort studies demonstrated that premature birth rates were 
24-33.9% in pregnant women with T1DM, and previous 
studies reported values ranging from 26.2% to 31.1% [22].
Cesarean section. Women with DM generally have 
higher cesarean section rates. The frequency of this pro-
cedure in pregnant women with DM worldwide is about 
42.7-78%, compared to a much lower rate in the general 
population (20%). The number of cesarean sections does 
not significantly vary in pregnant women with T1DM and 
T2DM. A number of DM-induced factors (maternal obe-
sity, fetal macrosomia, polyhydramnios and diabetic mi-
crovascular complications) are also associated with an in-
creased risk of surgery. Simultaneously with the protection 
of the newborn from hypoxic-ischemic cerebral lesions and 
the complications related to macrosomia by avoiding vagi-
nal birth, the potential side effects of a cesarean surgery are 
delayed or discontinued breastfeeding and respiratory mor-
bidity (transient tachypnea of the newborn or surfactant 
deficiency). These complications frequently lead to the ad-
mission of the newborn to the neonatal intensive care unit 
or resuscitation unit and separation of the mother from the 
child [21, 22].
Neonatal adverse outcomes
Respiratory distress syndrome. Neonates from moth-
ers with DM have an increased risk of respiratory disorders. 
The incidence of respiratory distress syndrome is 5-6 times 
higher for any gestational age compared to non-diabetic 
pregnancies. Respiratory distress syndrome is typical in 
newborns with DF, with a frequency of 13-40% in neonates 
of mothers with PGDM and up to 5% in neonates of mo-
thers with GDM [3, 8, 14, 15, 18, 20].
The pathogenesis of respiratory distress syndrome in 
neonates from mothers with DM is poorly understood, but 
several theories are possible. First, hyperinsulinemia inhib-
its the synthesis and secretion of surfactant by type 2 pneu-
mocytes with a delayed pulmonary maturation. Secondly, 
these children are often prematurely born with surfactant 
deficiency. Therefore, there is a direct adverse impact of 
hyperglycemia on the fetal metabolism of lung surfactant. 
Third, cesarean delivery due to macrosomia increases the 
risk of transient tachypnea in the newborn, while polycy-
themia predisposes the neonate to persistent lung hyperten-
sion. Finally, the cause of respiratory distress syndrome may 
also be meconium aspiration syndrome and hypertrophic 
cardiomyopathy. Nevertheless, respiratory distress syn-
drome affects newborns in pregnancies with severe PGDM. 
Frequency and risk of respiratory distress syndrome in 
GDM cannot be accurately determined due to insufficient 
data [3, 7, 8, 14, 15, 18, 20].
Metabolic, electrolytic and hematological neonatal 
disorders are associated with fetal hyperinsulinemia [18].
Hypoglycemia is the most common metabolic compli-
cation secondary to fetal hyperinsulinemia with a preva-
lence ranging from 25% to 76% depending on the definition 
of hypoglycemia threshold and maternal glycemic control at 
birth. However, in the vast majority of cases it is biochemi-
cal hypoglycemia, i.e. asymptomatic neonatal hypoglyce-
mia. Pregnant women with the highest basal glucose level 
have infants with the highest frequency of neonatal clinical 
hypoglycemia – 5-7%. The risk of hypoglycemia is the high-
est in large for gestational age infants and premature new-
borns [3, 15, 18, 25, 50].
A recent study defined capillary blood glucose levels as 
normal (≥2.5 mmol / l), mild hypoglycemia (2.2-2.4 mmol / 
l), moderate hypoglycemia (1.6-2.1 mmol / l) and severe hy-
poglycemia (<1.6 mmol / l). Among newborns from preg-
nant women with GDM, the prevalence of hypoglycemia 
was 25%: 12.1% had mild hypoglycemia, 10.5% moderate 
hypoglycemia and only 2.6% severe hypoglycemia [50].
Hypocalcaemia is detected at a calcium concentration 
of <2 mmol / l (<7 mg / dl) or ionized calcium concentra-
tion that is <1.1 mmol / l (<4 mg / dl) [14]. These complica-
tions occur up to 50% of cases, being usually associated with 
hyperphosphataemia and occasionally with hypomagnesae-
mia, all of which rarely have clinical significance. The etiol-
ogy of neonatal hypocalcaemia is unclear, but severe DM 
and neonatal hypoparathyroidism may be possible causes 
[3, 18, 20].
Polycythemia (a hematocrit that is > 65%) occurs in 13-
33% of cases [14, 18, 20], is more commonly determined 
in neonates from mothers with DM. Relative cell hypoxia 
determines an increased erythropoietin secretion, which 
in return increases fetal erythrocyte production. Neonatal 
polycythemia can cause excessive neonatal jaundice by red 
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cell lysis and blood clotting syndrome with complications 
caused by vascular stasis [3, 18, 20]. Hyperbilirubinaemia 
occurs in 11-29% of cases [14, 15, 18, 20].
Hypertrophic cardiomyopathy
DM in pregnant women affects the fetal heart structur-
ally (cardiac malformations, hypertrophic cardiomyopathy) 
and functionally (even in the absence of structural changes) 
with long-term consequences. Fetal hyperinsulinemia, as a 
result of abnormal maternal glycemic control, causes hyper-
plasia and hypertrophy of the fetal myocardium with the de-
velopment of hypertrophic cardiomyopathy - interventricu-
lar septal hypertrophy and, to a lesser extent, ventricular 
hypertrophy with left ventricular outflow tract obstruction. 
However, clinical experience shows that even infants of DM 
women with adequate glycemic control may have septal hy-
pertrophy. Therefore, other maternal major risk factors that 
affect the fetal heart were identified, such as hypertriglyc-
eridemia, obesity, increased oxidative stress and placental 
factors [8, 14, 20].
Hypertrophic cardiomyopathy occurs in 25-35% of 
infants born to mothers with DM and sometimes it leads 
to significant morbidity and mortality, depending on the 
severity and extent of cardiac hypertrophy and aortic ob-
struction. Fortunately, most cases of hypertrophic cardio-
myopathy are transient and asymptomatic, do not require 
treatment and have a spontaneous echocardiographic reso-
lution in the first months after birth [8, 14, 20].
Perinatal mortality. Until the discovery of insulin, 
pregnancies in women with DM were often associated 
with perinatal mortality. The perinatal mortality rate was 
around 65%, and maternal mortality was up to 30%. Insulin 
reduced maternal mortality by reducing the frequency of 
diabetic ketoacidosis, improving the fertility of women with 
DM, but perinatal mortality, although reduced, remained 
high [13,22].
Perinatal mortality in pregnant women with T1DM is 
5 times higher, with PGDM - 4 times higher and neonatal 
mortality in pregnant women with DM of any type – 15 times 
higher compared to the general population [18, 20, 21]. One 
of the largest recent population-based studies revealed that 
perinatal mortality is 3 times higher and infant mortality 9 
times higher in pregnant women with PGDM compared to 
those without DM. Major congenital abnormalities, mater-
nal hypertension, and premature birth are important fac-
tors in increasing the mortality of children born of diabetic 
mothers. Overall, the perinatal mortality rate is almost iden-
tical for mothers with T1DM and T2DM [18].
Studies with fetal blood sampling confirm that hyper-
glycemia is associated with fetal hypoxia and acidosis. In 
all types of DM there are additional risk factors associated 
with perinatal mortality – diabetic angiopathy, hyperten-
sion and IUGR. In T2DM and GDM, compared to pregnant 
women without DM, there is a so-called “triad” of factors 
for intrauterine death – the relatively greater age of pregnant 
women, higher incidence of obesity and high blood pres-
sure [13]. Although several factors may influence the peri-
natal mortality rate, the blood glucose threshold <6.1 mmol 
/ l (<110 mg / dl) is possibly a major factor in preventing this 
complication. However, unlike PGDM, the increase in the 
fetal death rate in the 2nd and 3rd trimesters of pregnancy 
is questionable in GDM and can be attributed to previously 
undiagnosed T2DM [14].
A systematic review of the literature and meta-analysis 
of 33 observational studies, published in 2009, that com-
pared maternal and fetal outcomes in pregnant women with 
T1DM and T2DM, found that pregnant women with T2DM 
had a lower level of HbA1c at the first OB visit, but a higher 
incidence of perinatal mortality, with no significant differ-
ences in major congenital malformations, antenatal, and 
neonatal mortality. Therefore, despite lower glycemic disor-
ders, women with T2DM, compared to women with T1DM, 
did not show better perinatal outcomes [10].
The complications described above are short-term ad-
verse outcomes, but long-term consequences may also oc-
cur. Children born from pregnancies complicated with 
GDM are at a higher risk of developing obesity, glucose 
intolerance and DM in adolescence and early adulthood. 
The lifetime risk to develop T1DM for children of diabetic 
mothers is 1.3%, and for children of diabetic fathers is 5.7%, 
while the risk of developing T1DM is much higher - about 
50% [18].
Conclusions
1. Maternal diabetes, predominantly PGDM, has a sig-
nificant impact on the incidence of both short-and-long- 
term complications in the fetus and newborn.
2. Short-term adverse outcomes include fetal complica-
tions (diabetic fetopathy, macrosomia, IUGR, congenital 
malformations, fetal antenatal death), complications related 
to labor and delivery (shoulder dystocia, birth injuries, in-
tranatal death) and neonatal adverse outcomes (respiratory 
distress syndrome, metabolic, electrolytic and hematologi-
cal neonatal disorders, hypertrophic cardiomyopathy, peri-
natal mortality).
3. Long-term fetal outcomes include overweight and 
obesity, impaired glucose tolerance or 
T2DM, metabolic syndromes with an increased risk of 
cardiovascular disease and subtle neurophysiologic dys-
function.
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